Is Fenelidone (Keshenda) a hormonal drug and its safety analysis

Finerenone (Finerenone) is a selective mineral corticoid receptor antagonist (MRA), mainly used in patients with chronic kidney disease and diabetes to slow down the deterioration of renal function and the occurrence of cardiovascular events. Although its target is the mineralocorticoid receptor, strictly speaking, fenelidone is not a hormonal drug in the traditional sense. It is not a glucocorticoid or mineral corticosteroid naturally secreted in the body, but a synthetic small molecule targeted drug that exerts pharmacological effects by selectively blocking receptors.

In terms of its mechanism of action, fenelinone inhibits excessive activation of mineralocorticoid receptors and reduces fibrosis and inflammatory responses in the kidneys and cardiovascular system, thereby protecting renal function and reducing cardiovascular risk. This selective effect makes it safer than traditional spironolactone drugs with a lower incidence of side effects, especially in terms of the risk of hyperkalemia and hormone-related adverse reactions.

In terms of safety, clinical studies show that fenelidone is generally well tolerated. The most common adverse reactions are hyperkalemia and mild blood pressure changes, which can usually be detected and managed early by regular monitoring of potassium levels and blood pressure. For patients with severe renal insufficiency or previous hyperkalemia, doctors will adjust the dose or implement monitoring interventions based on individual circumstances to ensure medication safety.

Overall, fenelidone is a non-traditional hormonal small molecule drug that exerts a protective effect by selectively inhibiting mineralocorticoid receptors. It is relatively safe, but it is still necessary to pay attention to monitoring of serum potassium and renal function. During use, patients should take the medication as directed by their doctor, regularly review blood indicators, and adjust the dosage according to the doctor's recommendations to achieve the treatment goals of maximum efficacy and minimum risk.

Reference link:https://www.drugs.com